BTG offers value beyond the dose for TheraSphere™ with a complete suite of training and support programs, providing expert guidance throughout the treatment process with the ultimate goal of improving patient outcomes.
Value Beyond the Dose

PERSONALISED DOSIMETRY

Programs that simplify, accelerate and personalise dosimetry with TheraSphere™
Opportunities to learn about TheraSphere™ and share best practices

- Centres of Excellence
- Advanced Users Meetings
- Case Study Academy
- βETA Program
- Proctoring
Extensive clinical trials program and a clinical registry to advance treatment options for patients with liver cancer

- STOP-HCC
- EPOCH
- TARGET
- READ\textsuperscript{90}Y™ Registry
Guidance and expert support for optimising treatment with TheraSphere™

- Medical Liaisons
- Medical Preceptors
- Radiation Safety
TheraSphere™ is used in the treatment of hepatic neoplasia.¹

Common adverse effects include fatigue, pain, and nausea. The majority of adverse effects are mild to moderate in severity and are manageable or resolve over time. For more important safety information, please refer to the TheraSphere™ Instructions For Use at www.therasphere.com.¹⁻³


TheraSphere™ is manufactured for Biocompatibles UK Ltd, a BTG International group company. TheraSphere and the TheraSphere logo are trademarks of Theragenics Corporation, used under license by Biocompatibles UK Ltd. TheraSphere is a registered trademark in the US, EU and certain other territories. ‘Power Within’ is a trademark of Biocompatibles UK Ltd. ‘Simplit90Y’, ‘READ90Y’, ‘Imagine where we can go’, BTG and the BTG roundel logo are trademarks of BTG International Ltd. BTG and the BTG roundel logo are registered trademarks in the US, EU and certain other territories. All rights reserved.